Foghorn Therapeutics (FHTX) shares surged in the latest session on above-average trading volume, but the article cautions that recent earnings estimate revisions are unlikely to drive additional near-term upside.
Foghorn Therapeutics (FHTX) shares surged in the latest session on above-average trading volume, but the article cautions that recent earnings estimate revisions are unlikely to drive additional near-term upside.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
-0.05
Ticker Sentiment
